IRLAB Therapeutics AB (publ) (IRLAB-A) — Capital Reinvestment Ratio

Latest as of September 2021: 0.00x

IRLAB Therapeutics AB (publ) (IRLAB-A) has a Capital Reinvestment Ratio of 0.00x as of September 2021, meaning it reinvests 0% of its operating cash flow (Skr202.83 Million) in capital expenditures (Skr137.00K). See IRLAB Therapeutics AB (publ) (IRLAB-A) net asset quality to measure how much of total assets are equity-financed.

Capital Reinvestment Ratio

0.00x

Capex / Operating Cash Flow

Operating Cash Flow

Skr202.83 Million

SEK

Capital Expenditures

Skr137.00K

SEK

Data as of

Sep 2021

Most recent filing

IRLAB Therapeutics AB (publ) Capital Reinvestment Ratio (2021–2021)

This chart tracks IRLAB Therapeutics AB (publ)'s Capital Reinvestment Ratio across 1 annual periods. Check how aggressively does IRLAB Therapeutics AB (publ) reinvest cash to assess the company's total reinvestment commitment from operating cash flow.

Annual Capital Reinvestment Ratio for IRLAB Therapeutics AB (publ) (2021–2021)

Year-by-year Capital Reinvestment Ratio for IRLAB Therapeutics AB (publ) from 2021 to 2021. For live market cap and broader valuation context, see IRLAB Therapeutics AB (publ) market capitalisation.

Year	Reinvestment Ratio	Operating CF (SEK)	Capital Expenditures	YoY Change
2021	0.01x	Skr128.64 Million	Skr708.00K	—

Capital Reinvestment Ratio = ABS(Capital Expenditures) / Operating Cash Flow